See more : Mufin Green Finance Limited (MUFIN.NS) Income Statement Analysis – Financial Results
Complete financial analysis of QuidelOrtho Corporation (QDEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of QuidelOrtho Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Archidply Industries Limited (ARCHIDPLY.BO) Income Statement Analysis – Financial Results
- Mirza International Limited (MIRZAINT.NS) Income Statement Analysis – Financial Results
- Ricoh Company, Ltd. (RICOY) Income Statement Analysis – Financial Results
- WP Energy Public Company Limited (WP.BK) Income Statement Analysis – Financial Results
- AXM Pharma, Inc. (AXMP) Income Statement Analysis – Financial Results
QuidelOrtho Corporation (QDEL)
About QuidelOrtho Corporation
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00B | 3.27B | 1.70B | 1.66B | 534.89M | 522.29M | 277.74M | 191.60M | 196.13M | 182.62M | 175.41M | 155.74M | 158.60M | 113.34M | 164.28M | 128.13M | 118.07M | 106.02M | 92.30M | 78.69M | 95.11M | 76.27M | 74.06M | 68.35M | 47.20M | 45.70M | 41.90M | 34.50M | 31.10M | 28.40M | 27.70M | 26.50M | 27.80M | 9.00M | 8.70M | 6.10M | 7.50M | 9.50M |
| Cost of Revenue | 1.50B | 1.33B | 427.66M | 312.81M | 214.09M | 206.57M | 121.60M | 73.41M | 71.69M | 74.18M | 66.98M | 61.29M | 62.87M | 52.61M | 55.22M | 50.21M | 48.57M | 44.82M | 37.10M | 35.23M | 42.81M | 38.27M | 35.27M | 36.50M | 22.80M | 21.10M | 17.20M | 13.90M | 14.20M | 13.80M | 13.20M | 12.90M | 13.70M | 3.70M | 5.30M | 4.30M | 8.60M | 3.60M |
| Gross Profit | 1.49B | 1.94B | 1.27B | 1.35B | 320.81M | 315.71M | 156.14M | 118.19M | 124.44M | 108.44M | 108.43M | 94.46M | 95.74M | 60.73M | 109.06M | 77.93M | 69.49M | 61.20M | 55.20M | 43.46M | 52.29M | 38.01M | 38.78M | 31.85M | 24.40M | 24.60M | 24.70M | 20.60M | 16.90M | 14.60M | 14.50M | 13.60M | 14.10M | 5.30M | 3.40M | 1.80M | -1.10M | 5.90M |
| Gross Profit Ratio | 49.85% | 59.28% | 74.82% | 81.17% | 59.98% | 60.45% | 56.22% | 61.68% | 63.45% | 59.38% | 61.82% | 60.65% | 60.36% | 53.58% | 66.39% | 60.82% | 58.86% | 57.72% | 59.80% | 55.22% | 54.98% | 49.83% | 52.37% | 46.59% | 51.69% | 53.83% | 58.95% | 59.71% | 54.34% | 51.41% | 52.35% | 51.32% | 50.72% | 58.89% | 39.08% | 29.51% | -14.67% | 62.11% |
| Research & Development | 246.80M | 190.50M | 95.70M | 84.29M | 52.55M | 51.65M | 33.64M | 38.67M | 35.51M | 37.91M | 34.19M | 27.72M | 26.33M | 24.57M | 12.53M | 11.15M | 12.86M | 13.05M | 12.83M | 11.34M | 8.47M | 6.75M | 6.20M | 7.05M | 7.90M | 7.90M | 6.70M | 4.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 748.10M | 594.20M | 84.25M | 66.59M | 52.76M | 44.95M | 29.19M | 27.06M | 29.45M | 25.81M | 26.26M | 20.64M | 22.80M | 18.47M | 16.78M | 12.79M | 31.66M | 29.74M | 29.18M | 28.84M | 28.51M | 25.85M | 0.00 | 8.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 15.10M | 26.80M | 175.33M | 133.96M | 111.11M | 108.99M | 67.25M | 47.82M | 47.89M | 41.53M | 33.83M | 30.32M | 25.75M | 23.97M | 23.35M | 20.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 763.20M | 621.00M | 259.57M | 200.54M | 163.87M | 153.94M | 96.44M | 74.88M | 77.33M | 67.34M | 60.09M | 50.96M | 48.55M | 42.44M | 40.13M | 33.68M | 31.66M | 29.74M | 29.18M | 28.84M | 28.51M | 25.85M | 24.49M | 25.19M | 15.80M | 15.70M | 14.20M | 13.90M | 18.90M | 16.00M | 13.20M | 11.70M | 17.50M | 4.70M | 5.60M | 5.90M | 7.20M | 5.50M |
| Other Expenses | 345.30M | 144.80M | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 9.07M | 8.86M | 8.83M | 31.00K | -30.00K | 7.12M | 6.73M | 1.36M | 4.48M | 5.49M | 4.58M | 18.48M | 1.46M | 2.06M | 1.95M | 4.37M | 1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.36B | 956.30M | 355.27M | 284.84M | 216.42M | 205.59M | 130.08M | 122.63M | 121.70M | 114.09M | 102.44M | 85.61M | 82.00M | 73.75M | 54.02M | 49.31M | 50.01M | 47.36M | 60.49M | 41.64M | 39.03M | 34.54M | 35.06M | 34.21M | 27.00M | 26.70M | 23.40M | 20.10M | 20.80M | 17.50M | 14.50M | 13.10M | 19.30M | 5.20M | 6.20M | 6.50M | 7.70M | 6.00M |
| Cost & Expenses | 2.86B | 2.29B | 782.93M | 597.65M | 430.51M | 412.16M | 251.69M | 196.04M | 193.39M | 188.27M | 169.42M | 146.90M | 144.86M | 126.35M | 109.24M | 99.51M | 98.58M | 92.18M | 97.59M | 76.88M | 81.84M | 72.81M | 70.33M | 70.72M | 49.80M | 47.80M | 40.60M | 34.00M | 35.00M | 31.30M | 27.70M | 26.00M | 33.00M | 8.90M | 11.50M | 10.80M | 16.30M | 9.60M |
| Interest Income | 2.20M | 1.30M | 300.00K | 600.00K | 14.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.00K | 41.00K | 203.00K | 214.00K | 372.00K | 1.69M | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 178.90M | 75.70M | 5.71M | 9.62M | 14.79M | 24.28M | 17.59M | 11.76M | 12.04M | 1.78M | 777.00K | 1.25M | 2.08M | 2.35M | 767.00K | 671.00K | 736.00K | 0.00 | 17.92M | 0.00 | 4.55M | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 457.20M | 283.60M | 54.38M | 49.09M | 51.79M | 46.27M | 30.76M | 31.87M | 8.86M | 8.83M | 8.17M | 6.94M | 7.12M | 6.73M | 1.36M | 4.48M | 9.85M | 9.11M | 5.47M | 6.21M | 6.60M | 6.15M | 8.15M | 6.53M | 3.30M | 3.10M | 2.50M | 2.10M | 1.90M | 1.50M | 1.30M | 1.40M | 1.80M | 500.00K | 600.00K | 600.00K | 500.00K | 500.00K |
| EBITDA | 545.60M | 1.09B | 955.44M | 1.09B | 143.76M | 133.93M | 40.31M | 18.78M | 11.59M | 19.16M | 29.74M | 15.79M | 31.38M | -2.75M | 59.28M | 39.12M | 31.11M | 22.94M | 176.00K | 7.37M | 21.19M | 11.71M | 10.43M | 5.21M | 600.00K | 900.00K | 3.80M | 2.50M | -2.00M | -1.40M | 1.00M | 1.90M | -3.40M | 600.00K | -2.20M | -4.10M | -8.30M | 400.00K |
| EBITDA Ratio | 18.20% | 33.81% | 53.91% | 64.03% | 19.51% | 21.09% | 9.38% | 2.42% | 5.91% | 1.74% | 8.10% | 10.14% | 13.28% | -5.35% | 34.56% | 27.14% | 24.95% | 21.13% | 18.56% | 9.36% | 22.77% | 10.00% | 14.08% | 6.22% | -7.84% | -0.44% | 1.91% | 5.22% | -8.68% | -9.86% | 3.61% | 3.02% | -14.39% | 15.56% | -27.59% | -27.87% | -120.00% | 2.11% |
| Operating Income | 139.10M | 843.70M | 906.07M | 1.06B | 52.59M | 95.93M | 9.55M | -4.44M | 2.74M | -9.21M | 4.17M | 8.85M | 13.74M | -15.29M | 52.55M | 28.62M | 19.49M | 13.83M | -5.29M | 1.82M | 11.06M | 3.47M | 3.18M | -4.67M | -2.60M | -2.10M | 1.30M | 500.00K | -3.90M | -2.90M | -300.00K | 500.00K | -5.20M | 100.00K | -2.80M | -4.70M | -8.80M | -100.00K |
| Operating Income Ratio | 4.64% | 25.83% | 53.34% | 63.81% | 9.83% | 18.37% | 3.44% | -2.32% | 1.40% | -5.04% | 2.37% | 5.68% | 8.66% | -13.49% | 31.99% | 22.34% | 16.50% | 13.05% | -5.73% | 2.31% | 11.63% | 4.54% | 4.29% | -6.83% | -5.51% | -4.60% | 3.10% | 1.45% | -12.54% | -10.21% | -1.08% | 1.89% | -18.71% | 1.11% | -32.18% | -77.05% | -117.33% | -1.05% |
| Total Other Income/Expenses | -168.20M | -107.80M | -5.70M | -20.01M | 24.59M | -32.55M | -17.59M | -11.76M | -12.04M | -1.78M | -1.41M | -1.24M | -2.26M | -2.13M | -400.00K | 1.15M | 1.04M | 1.20M | -37.00K | -232.00K | -573.00K | 2.11M | 19.00K | -1.16M | 4.10M | 700.00K | 2.30M | -400.00K | 700.00K | 1.40M | 700.00K | 400.00K | 600.00K | -800.00K | 200.00K | -2.40M | 700.00K | 100.00K |
| Income Before Tax | -29.10M | 735.90M | 900.36M | 1.04B | 77.18M | 63.38M | -8.04M | -16.20M | -9.30M | -10.98M | 3.43M | 7.61M | 11.48M | -17.42M | 52.15M | 29.77M | 20.52M | 15.03M | -5.33M | 1.58M | 10.50M | 2.84M | 3.86M | -4.78M | 1.40M | -1.50M | 3.60M | 1.30M | -3.20M | -1.50M | 700.00K | 900.00K | -4.60M | -700.00K | -2.60M | -7.10M | -8.10M | 100.00K |
| Income Before Tax Ratio | -0.97% | 22.53% | 53.01% | 62.61% | 14.43% | 12.14% | -2.89% | -8.45% | -4.74% | -6.01% | 1.96% | 4.89% | 7.24% | -15.37% | 31.74% | 23.23% | 17.38% | 14.18% | -5.77% | 2.01% | 11.04% | 3.72% | 5.21% | -6.99% | 2.97% | -3.28% | 8.59% | 3.77% | -10.29% | -5.28% | 2.53% | 3.40% | -16.55% | -7.78% | -29.89% | -116.39% | -108.00% | 1.05% |
| Income Tax Expense | -19.00M | 187.20M | 196.13M | 230.03M | 4.26M | -10.80M | 129.00K | -2.39M | -3.22M | -3.91M | -3.96M | 2.62M | 3.85M | -6.15M | 19.27M | 10.92M | 6.89M | -5.89M | 3.00M | 7.45M | -9.15M | 1.55M | 3.00M | 2.32M | -6.30M | -2.60M | 100.00K | -100.00K | 200.00K | -900.00K | 300.00K | 400.00K | 300.00K | 1.30M | 300.00K | 2.60M | -700.00K | 0.00 |
| Net Income | -10.10M | 548.70M | 704.20M | 810.29M | 72.92M | 74.18M | -8.17M | -13.81M | -6.08M | -7.07M | 7.39M | 4.99M | 7.63M | -11.27M | 32.88M | 18.85M | 13.63M | 21.72M | -9.26M | -6.29M | 19.65M | 1.29M | 854.00K | -5.85M | 7.70M | 1.10M | 3.50M | 600.00K | -4.10M | -2.00M | 700.00K | 800.00K | -5.50M | -1.20M | -3.10M | -7.30M | -8.10M | -100.00K |
| Net Income Ratio | -0.34% | 16.80% | 41.46% | 48.76% | 13.63% | 14.20% | -2.94% | -7.21% | -3.10% | -3.87% | 4.21% | 3.21% | 4.81% | -9.94% | 20.02% | 14.71% | 11.55% | 20.49% | -10.03% | -7.99% | 20.66% | 1.69% | 1.15% | -8.55% | 16.31% | 2.41% | 8.35% | 1.74% | -13.18% | -7.04% | 2.53% | 3.02% | -19.78% | -13.33% | -35.63% | -119.67% | -108.00% | -1.05% |
| EPS | -0.15 | 9.66 | 16.74 | 19.24 | 1.78 | 1.74 | -0.24 | -0.42 | -0.18 | -0.21 | 0.22 | 0.15 | 0.23 | -0.39 | 1.10 | 0.59 | 0.43 | 0.66 | -0.28 | -0.20 | 0.67 | 0.04 | 0.01 | -0.23 | 0.32 | 0.05 | 0.16 | 0.03 | -0.21 | -0.11 | 0.04 | 0.05 | -0.45 | -0.33 | -0.86 | -2.04 | -2.31 | -0.03 |
| EPS Diluted | -0.15 | 9.56 | 16.43 | 18.60 | 1.73 | 1.74 | -0.24 | -0.42 | -0.18 | -0.21 | 0.21 | 0.15 | 0.23 | -0.39 | 1.08 | 0.58 | 0.41 | 0.63 | -0.28 | -0.19 | 0.65 | 0.04 | 0.01 | -0.23 | 0.32 | 0.05 | 0.16 | 0.03 | -0.21 | -0.11 | 0.04 | 0.05 | -0.45 | -0.33 | -0.86 | -2.04 | -2.31 | -0.03 |
| Weighted Avg Shares Out | 66.80M | 56.80M | 42.08M | 42.12M | 40.86M | 42.55M | 33.73M | 32.71M | 33.77M | 33.69M | 34.94M | 33.70M | 32.90M | 28.58M | 29.96M | 31.85M | 32.03M | 32.99M | 32.53M | 31.49M | 29.18M | 28.82M | 28.29M | 24.88M | 24.06M | 22.00M | 22.00M | 20.00M | 19.52M | 18.18M | 17.50M | 14.00M | 12.34M | 3.61M | 3.60M | 3.58M | 3.51M | 3.33M |
| Weighted Avg Shares Out (Dil) | 66.80M | 57.40M | 42.87M | 43.59M | 43.11M | 42.55M | 33.73M | 32.71M | 34.10M | 34.45M | 34.95M | 33.70M | 33.32M | 28.58M | 30.42M | 32.61M | 33.00M | 34.37M | 32.53M | 32.39M | 30.37M | 29.63M | 29.28M | 24.88M | 24.06M | 22.00M | 22.79M | 20.00M | 19.52M | 18.18M | 17.50M | 14.00M | 12.34M | 3.61M | 3.60M | 3.58M | 3.51M | 3.33M |
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted
On Tuesday, QuidelOrtho Corporation QDEL priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the...
QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the “Offering”) by...
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm
NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,...
QuidelOrtho Stock Rises as Q3 Earnings & Revenues Beat Estimates
QDEL's third-quarter results reflect growth in non-respiratory revenues along with a lowering of operating expenses year over year. However, the gross margin declines in the reported quarter.
QuidelOrtho Corporation (QDEL) Q3 2024 Earnings Call Transcript
QuidelOrtho Corporation (NASDAQ:QDEL ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Juliet Cunningham – Vice President, Investor Relations Brian Blaser – President and Chief Executive Officer Joe Busky – Chief Financial Officer Conference Call...
QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates
QuidelOrtho (QDEL) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.90 per share a year ago.
Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders.
Source: https://incomestatements.info
Category: Stock Reports